𝔖 Bobbio Scriptorium

✦ LIBER ✦

263 ORAL Doxorubicin and cyclophosphamide (AC) followed by paclitaxel (T) with or without trastuzumab (H) as adjuvant therapy for patients with HER2-positive operable breast cancer (BC): combined analysis of NSABP B-31 and NCCTG N9831

Book ID: 118622843
Publisher: Elsevier Science
Year: 2005
Tongue: English
Weight: 138 KB
Volume: 3
Category: Article
ISSN: 1359-6349
DOI: 10.1016/s1359-6349(05)80561-0

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Cardiac safety analysis of the first sta

Cardiac safety analysis of the first stage of NSABP B-31, a randomized trial comparing the safety and efficacy of doxorubicin and cyclophosphamide (AC) followed by paclitaxel (T) to that of AC followed by paclitaxel plus trastuzumab (TH) in patients (pts) with operable, node-positive (N+), HER-2 overexpressing breast cancer (HER2+BC)

✍ C Geyer; J Bryant; E Romond; E Tan-Chiu; M Ewer; D Keefe; R Shannon; G Yothers; 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 541 KB

Seven-Year Follow-Up Assessment of Cardi

Seven-Year Follow-Up Assessment of Cardiac Function in NSABP B-31, a Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Paclitaxel (ACP) With ACP Plus Trastuzumab As Adjuvant Therapy for Patients With Node-Positive, Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer

✍ Zibelman, M.; Goldstein, L.J. 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 54 KB